Key facts
- Sansanima’s last known valuation is $2.9M (Apr 2025).
- It has raised $300K; the latest was Early Stage VC in May 2025.
- Notable investors include Cambridge Angels, ICURe, Mandashi, O2h Ventures, The University of Sheffield.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Sansanima
- ·The full record, as it builds
Funding rounds
No funding rounds for Sansanima are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sansanima
Developer of an in-vitro cell-based assay platform designed to replace animal testing. The company's technology precisely replicates the physiological intoxication processes of tetanus and botulinum toxins, addressing growing ethical concerns and regulatory pressure, providing manufacturers with a humane, reproducible alternative, ensuring product safety and efficacy in this critical therapeutic area.
- Sector
- Healthcare
- HQ
- Sheffield, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- sansanima.com/
- Ownership
- Privately Held (backing)
Sansanima doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sansanima shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sansanima in its N-PORT filings yet. We sweep new filings monthly.